Foster & Motley Inc. grew its position in Amgen Inc. (NASDAQ:AMGN) by 1.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 45,038 shares of the medical research company’s stock after purchasing an additional 707 shares during the period. Amgen comprises about 1.4% of Foster & Motley Inc.’s portfolio, making the stock its 22nd largest position. Foster & Motley Inc.’s holdings in Amgen were worth $7,757,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Skandinaviska Enskilda Banken AB publ acquired a new stake in Amgen in the first quarter worth $110,402,000. Swiss National Bank raised its holdings in shares of Amgen by 26.5% during the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after acquiring an additional 551,600 shares during the period. Bank of Nova Scotia raised its holdings in shares of Amgen by 414.4% during the first quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock worth $98,747,000 after acquiring an additional 484,868 shares during the period. AQR Capital Management LLC raised its holdings in shares of Amgen by 37.4% during the first quarter. AQR Capital Management LLC now owns 1,443,129 shares of the medical research company’s stock worth $236,775,000 after acquiring an additional 392,538 shares during the period. Finally, Morningstar Investment Services LLC raised its holdings in shares of Amgen by 283.8% during the first quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock worth $81,625,000 after acquiring an additional 367,894 shares during the period. Institutional investors own 78.10% of the company’s stock.
Amgen Inc. (NASDAQ AMGN) opened at 182.76 on Friday. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $191.10. The stock has a 50 day moving average of $183.15 and a 200 day moving average of $170.75. The firm has a market capitalization of $133.36 billion, a PE ratio of 16.65 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. During the same period in the prior year, the firm posted $2.84 earnings per share. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, equities analysts predict that Amgen Inc. will post $12.58 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.truebluetribune.com/2017/10/13/foster-motley-inc-has-7-76-million-position-in-amgen-inc-amgn.html.
In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.19% of the company’s stock.
A number of brokerages recently commented on AMGN. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $203.00 price objective on shares of Amgen in a report on Friday, October 6th. Mizuho restated a “buy” rating and set a $198.00 price objective on shares of Amgen in a report on Friday, October 6th. Morgan Stanley restated an “overweight” rating and set a $196.00 price objective (up from $189.00) on shares of Amgen in a report on Friday, October 6th. Credit Suisse Group restated a “neutral” rating and set a $186.00 price objective (up from $177.00) on shares of Amgen in a report on Friday, September 29th. Finally, Cann restated a “buy” rating and set a $203.00 price objective on shares of Amgen in a report on Friday, October 6th. Ten analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $189.99.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.